The Canadian Health Ministry announced a review into whether diabetes drug Lantus, one of the most widely sold drugs worldwide by pharmaceutical giant Sanofi-Aventis, increases the risk of cancer.
"Health Canada is informing Canadians of an ongoing safety review of the potential association between the diabetes drug Lantus (insulin glargine) and an increased risk of developing cancer," the ministry said in a statement.Similar reviews have already been launched by the US Food and Drug Administration and the European Medicines Agency after four studies examining the relationship between the drug and cancer incidence were published.
Three of the studies reported that the synthetic insulin, used to control blood sugar in people with type 1 and type 2 diabetes, was associated with a slightly higher risk of cancer, but the fourth study found no relationship.
"In all studies, the number of patients who developed cancer was small," the Canadian Health Ministry noted.
Blood Sugar-Conversion
Our easy to use blood sugar calculator helps you to get your blood sugar conversion results either in mg/dl used by the American system or in mmol/l used by the British system, which is accepted worldwide.
Our easy to use blood sugar calculator helps you to get your blood sugar conversion results either in mg/dl used by the American system or in mmol/l used by the British system, which is accepted worldwide.
The ministry cautioned diabetics against stopping treatment with Lantus, noting the dangers posed by uncontrolled blood sugar.
Advertisement
Human Insulin Cuts Cancer Risk Among Diabetics
Diabetes patients' risk of cancer increases if they use the long-acting insulin analogue glargine instead of human insulin, according to a study.
Diabetes patients' risk of cancer increases if they use the long-acting insulin analogue glargine instead of human insulin, according to a study.
Source-AFP
LIN
